Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
11
×
Tags
biotech
11
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
11
×
indiana blog main
11
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
11
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
amgen
clinical trials
abbvie
cancer
novartis
startups
biogen
bristol-myers squibb
cancer immunotherapy
eli lilly
gene therapy
What
roundup
bio
cancer
crispr
days
news
abbvie’s
biotech
black
companies
conference
day
diamond’s
drug
drugs
labor
nash
new
opioid
remains
therapeutics
according
acquisitions
ahead
akcea
albert
alliance
allogene
annual
appetite
approval
ash
august
barbecuing
barcelona
biggest
biofourmis
biogen’s
biopharmaceutical
bourla
Language
unset
unknown
Current search:
glaxosmithkline
×
photo
×
" indiana blog main "
×
" seattle blog main "
×
biotech
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More